Nirmatrelvir/ritonavir reduces risk of COVID-19 hospitalizations among outpatient elderly patients in SG | Multidisciplinary

A retrospective cohort study assessed the real-world effectiveness of nirmatrelvir/ritonavir in nonhospitalized elderly patients during transmission of Omicron sub-variants in Singapore.¹

1. Wee LE, et al. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission. Clinical Microbiology and Infection 2023;29(10):1328-1333.

Resources

Nirmatrelvir-ritonavir reduces risk of COVID-19 hospitalizations